On the other hand, ursodeoxycholic acid, a drug for primary biliary cirrhosis, along with vitamin E (400 IU twice daily) for the same period (2 years) had no effect on inflammation in 48 patients with advanced nonalcoholic fatty liver disease (NAFLD) but decreased alanine transaminase (ALT) and steatosis [91]. The gene discussed is GPT; the disease is primary biliary cholangitis.